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OBJECTIVES This is a randomized controlled study of anemic patients with severe congestive heart failure
(CHF) to assess the effect of correction of the anemia on cardiac and renal function and
hospitalization.
BACKGROUND Although mild anemia occurs frequently in patients with CHF, there is very little information
about the effect of correcting it with erythropoietin (EPO) and intravenous iron.
METHODS Thirty-two patients with moderate to severe CHF (New York Heart Association [NYHA]
class III to IV) who had a left ventricular ejection fraction (LVEF) of #40% despite
maximally tolerated doses of CHF medications and whose hemoglobin (Hb) levels were
persistently between 10.0 and 11.5 g% were randomized into two groups. Group A (16
patients) received subcutaneous EPO and IV iron to increase the level of Hb to at least 12.5
g%. In Group B (16 patients) the anemia was not treated. The doses of all the CHF
medications were maintained at the maximally tolerated levels except for oral and intravenous
(IV) furosemide, whose doses were increased or decreased according to the clinical need.
RESULTS Over a mean of 8.2 6 2.6 months, four patients in Group B and none in Group A died of
CHF-related illnesses. The mean NYHA class improved by 42.1% in A and worsened by
11.4% in B. The LVEF increased by 5.5% in A and decreased by 5.4% in B. The serum
creatinine did not change in A and increased by 28.6% in B. The need for oral and IV
furosemide decreased by 51.3% and 91.3% respectively in A and increased by 28.5% and
28.0% respectively in B. The number of days spent in hospital compared with the same period
of time before entering the study decreased by 79.0% in A and increased by 57.6% in B.
CONCLUSIONS When anemia in CHF is treated with EPO and IV iron, a marked improvement in cardiac
and patient function is seen, associated with less hospitalization and renal impairment and less
need for diuretics. (J Am Coll Cardiol 2001;37:1775–80) © 2001 by the American College
of Cardiology
Anemia of any cause is known to be capable of causing
congestive heart failure (CHF) (1). In patients hospitalized
with CHF the mean hemoglobin (Hb) is about 12 g% (2,3),
which is considered the lower limit of normal in adults (4).
Thus, anemia appears to be common in CHF. Recently, in
142 patients in our special CHF outpatient clinic, we found
that as the CHF worsened, the mean Hb concentration
decreased, from 13.7 g% in mild CHF (New York Heart
Association [NYHA] class I) to 10.9 g% in severe CHF
(NYHA 4), and the prevalence of a Hb ,12 g% increased
from 9.1% in patients with NYHA 1 to 79.1% in those with
NYHA 4 (5). The Framingham Study has shown that
anemia is an independent risk factor for the production of
CHF (6). Despite this association of CHF with anemia, its
role is not mentioned in the 1999 U.S. guidelines for the
diagnosis and treatment of CHF (7), and many studies
consider anemia to be only a rare contributing cause of
hospitalization for CHF (8,9).
Recently, we performed a study in which the anemia of
severe CHF that was resistant to maximally tolerated doses of
standard medications was corrected with a combination of
subcutaneous (sc) erythropoietin (EPO) and intravenous iron
(IV Fe) (5). We have found this combination to be safe,
effective and additive in the correction of the anemia of chronic
renal failure (CRF) in both the predialysis period (10) and the
dialysis period (11). The IV Fe appears to be more effective
than oral iron (12,13). In our previous study of CHF patients
(5), the treatment resulted in improved cardiac function,
improved NYHA functional class, increased glomerular filtra-
tion rate, a marked reduction in the need for diuretics and a
92% reduction in the hospitalization rate compared with a
similar time period before the intervention.
In the light of these positive results, a prospective
randomized study was undertaken to determine the effects
of the correction of anemia in severe symptomatic CHF
resistant to maximally tolerated CHF medication.
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MATERIALS AND METHODS
Patients. Thirty-two patients with CHF were studied.
Before the study, the patients were treated for least six
months in the CHF clinic with maximally tolerated doses of
angiotensin-converting enzyme inhibitors, the beta-
blockers bisoprolol or carvedilol, aldospirone, long-acting
nitrates, digoxin and oral and intravenous (IV) furosemide.
In some patients these agents could not be given because of
contraindications and in others they had to be stopped
because of side effects. Despite this maximal treatment the
patients still had severe CHF (NYHA class $III), with
fatigue and/or shortness of breath on even mild exertion or
at rest. All had levels of Hb in the range of 10 to 11.5 g%
on at least three consecutive visits over a three-week period.
All had a LVEF of ,40%. Secondary causes of anemia
including hypothyroidism, and folic acid and vitamin B12
deficiency were ruled out and there was no clinical evidence
of gastrointestinal bleeding.
The patients were randomized consecutively into two
groups: Group A, 16 patients, was treated with sc EPO and
IV Fe to achieve a target Hb of at least 12.5 g%. Group B,
16 patients, did not receive the EPO and IV Fe.
Treatment protocol for correction of anemia. All patients
in Group A received the combination of sc EPO and IV Fe.
The EPO was given once a week at a starting dose of 4,000
international units (IU) per week sc and the dose was
increased to two or three times a week or decreased to once
every few weeks as necessary to achieve and maintain a
target Hb of 12.5 g%. The IV Fe (Venofer-Vifor Interna-
tional, Switzerland), a ferric sucrose product, was given in a
dose of 200 mg IV in 150 ml saline over 60 min every two
weeks until the serum ferritin reached 400 mg/l or the %Fe
saturation (%Fe Sat is serum iron/total iron binding capac-
ity 3 100) reached 40% or the Hb reached 12.5g%. The IV
Fe was then given at longer intervals as needed to maintain
these levels.
Investigations. Visits to the clinic were at two- to three-
week intervals depending on the patient’s status. This was
the same frequency of visits to the CHF clinic as before the
intervention study. A complete blood count, serum creati-
nine, potassium and ferritin and %Fe Sat were performed on
every visit. The blood pressure was measured by an elec-
tronic device on every visit. The LVEF was measured
initially and at four- to six-month intervals by MUGA
radioisotope ventriculography. This technique measures the
amount of blood in the ventricle at the end of systole and at
the end of diastole, thus giving a very accurate assessment of
the ejection fraction. It has been shown to be an accurate
and reproducible method of measuring the ejection fraction
(14).
Hospital records were reviewed at the end of the inter-
vention period to compare the number of days hospitalized
during the study with the number of days hospitalized
during a similar period when the patients were treated in the
CHF clinic before the initial randomization and entry into
the study. Clinic records were reviewed to evaluate the types
and doses of CHF medications used before and during the
study.
The mean follow-up for patients was 8.2 6 2.7 months
(range 5 to 12 months). The study was done with the
approval of the local ethics committee.
Statistical analysis. An analysis of variance with repeated
measures (over time) was performed to compare the two
study groups (control vs. treatment) and to assess time trend
and the interactions between the two factors. A separate
analysis was carried out for each of the outcome parameters.
The Mann-Whitney test was used to compare the change in
NYHA class between two groups. All the statistical analysis
was performed by SPSS (version 10).
RESULTS
The mean age in Group A (EPO and Fe) was 75.3 6 14.6
years and in group B was 72.2 6 9.9 years. There were 11
and 12 men in Groups A and B, respectively. Before the
study the two groups were similar in cardiac function,
comorbidities, laboratory investigations and medications
(Tables 1, 2 and 3), except for IV furosemide (Table 3),
which was higher in the treatment group. The mean NYHA
class of Group A before the study was 3.8 6 0.4 and was
3.5 6 0.5 in Group B. The contributing factors to CHF in
Groups A and B, respectively, are seen in Table 1 and were
similar. The main contributing factors to CHF were con-
sidered to be ischemic heart disease (IHD) in 11 and 10
patients respectively, hypertension in two and two patients,
valvular heart disease in two and two patients, and idio-
pathic cardiomyopathy in one and two patients, respectively.
A significant change after treatment was observed in the
two groups in the following parameters: IV furosemide, days
in hospital, Hb, ejection fraction, serum creatinine and
serum ferritin. In addition, the interaction between the
study group and time trend was significant in all measure-
ments except for blood pressure and %Fe Sat. This inter-
action indicates that the change over time was significantly
different in the two groups. For example, before treatment
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the level of oral furosemide was higher in the control group
(136.2 mg/day) compared with the treatment group
(132.2 mg/day). After treatment, while the dose of oral
furosemide of the treated patients was reduced to
64.4 mg/day the dose of the nontreated patients was
increased to 175 mg/day.
The same results of improvement in the treated group
and deterioration in the control group are expressed in the
following parameters: IV furosemide, days in hospital, Hb,
ejection fraction and serum creatinine.
The NYHA class was 3.8 6 0.4 before treatment and
2.2 6 0.7 after treatment in Group A and 3.5 6 0.7 before
treatment and 3.9 6 0.3 after treatment in Group B. The
improvement in NYHA class was significantly higher (p ,
0.0001) in the treatment group compared with the control
group (Table 4).
There were no deaths in Group A and four deaths in
Group B.
Case 1: A 71-year-old woman with severe mitral insuf-
ficiency and severe pulmonary hypertension (a pulmonary
artery [PA] pressure of 75 mm Hg) had persistent NYHA
4 CHF and died during mitral valve surgery seven months
after onset of the study. She was hospitalized for 21 days in
the seven months before randomization and for 28 days
during the seven months after randomization.
Case 2: A 62-year-old man with a longstanding history of
hypertension complicated by IHD, coronary artery bypass
graft (CABG) and atrial fibrillation had persistent NYHA 4
CHF and a PA pressure of 35 mm Hg, and died from
pneumonia and septic shock eight months after onset of the
study. He was hospitalized for seven days in the eight
months before randomization and for 21 days during the
eight months after randomization.
Case 3: A 74-year-old man with IHD, CABG, chronic
obstructive pulmonary disease, a history of heavy smoking
and diabetes had persistent NYHA 4 CHF and a PA
pressure of 28 mm Hg, and died of pulmonary edema and
cardiogenic shock nine months after onset of the study. He
was hospitalized for 14 days in the nine months before
randomization and for 41 days during the nine months after
randomization.
Case 4: A 74-year-old man with a history of IHD,
CABG, diabetes, dyslipidemia, hypertension and atrial
fibrillation, had persistent NYHA 4 CHF and a PA
pressure of 30 mm Hg, and died of pneumonia and septic
shock six months after onset of the study. He was hospi-
talized for five days in the six months before randomization
and for 16 days during the nine months after randomiza-
tion.
DISCUSSION
Main findings. The main finding of the present study is
that the correction of even mild anemia in patients with
symptoms of very severe CHF despite being on maximally
tolerated drug therapy resulted in a significant improvement
in their cardiac function and NYHA functional class. There
was also a large reduction in the number of days of
hospitalization compared with a similar period before the
intervention. Furthermore, all this was achieved despite a
marked reduction in the dose of oral and IV furosemide.
In the group in whom the anemia was not treated, four
Table 1. Medical Conditions and Contributing Factors to
Congestive Heart Failure in the 16 Patients Treated for the
Anemia and in the 16 Controls
Medical conditions
Treatment Control
No. % No. %
Ischemic heart disease 12 75 12 75
CABG 6 37.5 7 43.8
Diabetes 6 37.5 6 37.5
Hyperlipidemia 10 62.5 8 50
Hypertension 5 31.3 7 43.8
Chronic renal failure 8 50 8 50
Mitral regurgitation 4 25 3 18.8
Atrial fibrillation 2 12.5 3 18.8
Rheumatic heart disease 1 6.3 1 6.3
Idiopathic cardiomyopathy 1 6.3 2 12.5
Smoker 6 37.5 5 31.3
Peripheral vascular disease 0 0 1 6.3
CABG 5 coronary artery bypass graft.
Table 2. Number and Percentage of Cases Taking Each Medication and the Doses used in mg/
day in the Treatment and Control Groups During the Study
Medication
Treatment Control
No. % Dose, mg/d No. % Dose, mg/d
Digoxin 15 93.8 0.13 6 0.1 14 87.5 0.12 6 0.1
Nitrates 14 87.5 55.0 6 22.5 12 75.0 50.0 6 10.4
Aldospirone 15 93.8 28.3 6 5.3 16 100 38.3 6 35.8
Beta-blockers 13 81.3 11 68.8
Carvedilol 10 62.5 33.9 6 12.2 9 56.3 28.8 6 5.1
Bisoprolol 3 18.8 10.0 6 0 2 12.5 10.0 6 0
ACE inhibitors 14 87.5 14 87.5
Captopril 9 56.3 76.7 6 46.7 10 62.5 83.75 6 45.9
Enalapril 5 31.3 27.5 6 8.9 4 25.0 25.5 6 11.0
Angiotensin II receptor blockers 1 6.6 2 12.5
Losartan 1 6.6 50.0 6 0 2 12.5 50.0 6 0
The dose of these medications was not changed during the study.
ACE 5 angiotensin-converting enzyme.
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patients died during the study. In all four cases the CHF
was unremitting and contributed to the deaths. In addition,
for the group as a whole, the LVEF, the NYHA class and
the renal function worsened. There was also need for
increased oral and IV furosemide as well as increased
hospitalization.
Study limitations. The major limitations of this study are
the smallness of the sample size and the fact that random-
ization and treatment were not done in a blinded fashion.
Nevertheless, the two groups were almost identical in
cardiac, renal and anemia status; in the types and doses of
medication they were taking before and during the inter-
vention and in the number of hospitalization days before the
intervention. Although the results of this study, like those of
our previous uncontrolled study (5), suggest that anemia
may play an important role in the mortality and morbidity of
CHF, a far larger double-blinded controlled study should be
carried out to verify our findings.
Anemia as a risk factor for hospitalization and death in
CHF. Our results are consistent with a recent analysis of
91,316 patients hospitalized with CHF (15). Anemia was
found to be a stronger predictor of the need for early
rehospitalization than was hypertension, IHD or the pres-
ence of a previous CABG. A recent analysis of the Studies
Of Left Ventricular Dysfunction (SOLVD) (16) showed
that the level of hematocrit (Hct) was an independent risk
factor for mortality. During a mean follow-up of 33 months
the mortality was 22%, 27% and 34% for those with a Hct
of .40, 35 to 40 and ,35 respectively. The striking
response of our patients to correction of mild anemia
suggests that the failing heart may be very susceptible to
anemia. It has, in fact, been found in both animal (17) and
human studies (17–19) that the damaged heart is more
vulnerable to anemia and/or ischemia than is the normal
heart. These stimuli may result in a more marked reduction
in cardiac function than occurs in the normal heart and may
explain why, in our study, the patients were so resistant to
high doses of CHF medications and responded so well
when the anemia was treated.
Our findings about the importance of anemia in CHF are
not surprising when one considers that, in dialysis patients,
anemia has been shown to be associated with an increased
prevalence and incidence of CHF (20) and that correction
of anemia in these patients is associated with improved
cardiac function (21,22), less mortality (23,24) and fewer
hospitalizations (23,25).
Effect of improvement of CHF on CRF. Congestive
heart failure can cause progressive renal failure (26,27).
Renal ischemia is found very early on in patients with
cardiac dysfunction (28,29), and chronic ischemia may cause
progression of renal failure (30). Indeed, the development of
CHF in patients with essential hypertension has been found
Table 3. The Effect of Correction of Anemia by Intravenous Iron and Erythropoietin Therapy on Various Parameters in 16 Patients
in the Treatment (A) and 16 in the Control (B) Group
Parameter Time














IV furosemide mg/wk Before 49.3 27.6 76.7 36.8 0.03 0.001 NS ,0.0001
After 63.1 37.1 6.6 28.2
Oral furosemide mg/d Before 136.2 86.1 132.2 38.9 NS NS 0.023 ,0.0001
After 175.0 113.0 64.4 39.1
Days in hospital Before 9.9 4.8 13.8 7.2 NS 0.039 0.03 ,0.0001
After 15.6 9.8 2.9 6.6
Hb, g% Before 10.9 0.8 10.3 1.2 NS ,0.0001 0.0004 ,0.0001
After 10.8 0.8 12.9 1.1
Ejection fraction Before 28.4 7.6 30.8 12.6 NS NS ,0.013 ,0.0001
After 23.0 6.9 36.3 11.9
Serum creatine mg% Before 1.4 0.9 1.7 0.8 NS 0.022 NS 0.006
After 1.8 0.5 1.7 0.7
%Fe sat Before 22.5 16.7 25.1 12.9 NS NS 0.021 NS
After 21.8 16.5 31.3 8.6
Serum ferritin, mg/l Before 264.0 162.5 221.4 165.1 NS 0.003 NS 0.017
After 283.2 157.1 366.8 175.4
Diastolic BP, mm Hg Before 71.9 9.9 72.8 10.7 NS NS NS NS
After 72.2 10.8 73.1 12.2
Systolic BP, mm Hg Before 127.8 17.8 126.4 18.2 NS NS NS NS
After 127.0 21.4 127.9 20.2
p values are given for analysis of variance with repeated measures and for independent t tests for comparison of baseline levels between the two groups.
BP 5 blood pressure; Fe Sat 5 iron saturation; Hb 5 hemoglobin; IV 5 intravenous; NS 5 not stated; Std Dev. 5 standard deviation.
Table 4. Changes from Baseline to Final New York Heart
Association (NYHA) Class
Initial minus final
NYHA class 21 0 1 2 3 Total
Control 7 8 1 0 0 16
Treatment 0 1 7 7 1 16
The improvement in NYHA class was statistically higher (p , 0.0001) in the
treatment group compared with control.
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to be one of the most powerful predictors of the eventual
development of end-stage renal disease (31). Patients who
develop CHF after a myocardial infarction experience a fall
in the glomerular filtration rate (GFR) of about 1 ml/min/
month if the CHF is not treated (32).
In another recent analysis of the SOLVD study, treating
the CHF with both angiotensin-converting enzyme inhib-
itors and beta-blockers resulted in better preservation of the
renal function than did angiotensin-converting enzyme
inhibitors alone (26), suggesting that the more aggressive
the treatment of the CHF, the better the renal function is
preserved. In the present study, as in our previous one (5),
we found that the deterioration of GFR was prevented with
successful treatment of the CHF, including correction of
the anemia, whereas the renal function worsened when the
CHF remained severe. All these findings suggest that early
detection and treatment of CHF and systolic and/or dia-
stolic dysfunction from whatever cause could prevent the
deterioration not only of the cardiac function but of the
renal function as well. This finding has very broad implica-
tions in the prevention of CRF, because most patients with
advanced CRF have either clinical evidence of CHF or at
least some degree of systolic dysfunction (33). Systolic
and/or diastolic dysfunction can occur early on in many
conditions, such as essential hypertension (34), renal disease
of any cause (35,36) or IHD, especially after a myocardial
infarction (37). The early detection and adequate treatment
of this cardiac dysfunction, including correction of the
anemia, could prevent this cardiorenal insufficiency. To
detect cardiac dysfunction early on, one would need at least
an echocardiogram and MUGA radionucleotide ventricu-
lography. These tests should probably be done not only in
patients with signs and symptoms of CHF but in all patients
where CHF or systolic and/or diastolic dysfunction are
suspected, such as those with a history of heart disease or
suggestive changes of ischemia or hypertrophy on the
electrocardiogram, or in patients with hypertension or renal
disease.
Other positive cardiovascular effects of EPO treatment.
Another possible explanation for the improved cardiac
function in this study may be the direct effect that EPO
itself has on improving cardiac muscle function (38,39) and
myocardial cell growth (39,40) unrelated to its effect of the
anemia. In fact EPO may be crucial in the formation of the
heart muscle in utero (40). It may also improve endothelial
function (41). Erythropoietin may be superior to blood
transfusions not only because adverse reactions to EPO are
infrequent, but also because EPO causes the production and
release of young cells from the bone marrow into the blood.
These cells have an oxygen dissociation curve that is shifted
to the right of the normal curve, causing the release of much
greater amounts of oxygen into the tissues than occurs
normally (42). On the other hand, transfused blood consists
of older red cells with an oxygen dissociation curve that is
shifted to the left, causing the release of much less oxygen
into the tissues than occurs normally (42).
The combination of IV Fe and EPO. The use of IV Fe
along with EPO has been found to have an additive effect,
increasing the Hb even more than would occur with EPO
alone while at the same time allowing the dose of EPO to
be reduced (10–13). The lower dose of EPO will be
cost-saving and also reduce the chances of hypertension
developing (43). We used iron sucrose (Venofer) as our IV
Fe medication because, in our experience, it is extremely
well tolerated (10,11) and has not been associated with any
serious side effects in more than 1,200 patients over six
years.
Implications of treatment of anemia in CHF. The cor-
rection of anemia is not a substitute for the well-
documented effective therapy of CHF but seems to be an
important, if not vital, addition to the therapy. It is
surprising, therefore, that judging from the literature on
CHF, such an obvious treatment for improving CHF is so
rarely considered. We believe that correction of the anemia
will have an important role to play in the amelioration of
cardiorenal insufficiency, and that this improvement will
have significant economic implications as well.
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